AbbVie/Allergan's merger faces public opposition

Drugmakers have blamed high pricing on rebates demanded by PBMs for inclusion in formularies, while PBMs have insisted this is not the case and that all inclusion decisions are based on

Novo follows Sanofi, Lilly with insulin price cut in US

They denied they were responsible, pointing to the complexity of the health insurance system in the US and – in particular – pharmacy benefit managers (PBMs), which the drugmakers  claim have a vested ... With PBMs  blaming manufacturers for the

White House unveils plans to reimport medicines from Canada

This would allow pharma companies to bypass contracts with pharmacy benefit managers (PBMs), but is unlikely to have any takers from pharma, which has been quick to express its strong opposition ... PhRMA had been in support of proposals to ban the

PhRMA opposed to Senate drug price control plans

Other measures are also included, including an increase in the maximum rebate allowed under Medicaid, and forcing pharmacy benefit managers (PBMs) to disclose information on the discounts they are negotiating. ... PhRMA said in a statement that the

Another setback on pricing as Trump drops rebate plans

Shares in pharmacy benefit managers (PBMs) such as Cigna, UnitedHealth and CVS Health leaped upwards after it became clear that the measure – billed by the Department of Health and Human Services ... AARP. It was one of the few measures outlined by

The fight for affordable insulin

In April, in response to growing outrage over the problem (and the wider issue of rising drug prices), executives from pharma companies, pharmacy benefit managers (PBMs) and health insurers were hauled ... We know a lot of their messages align with those

The handover: Pfizer reshapes itself for a new era

Read has instead reiterated his support for ending the US rebate system between pharma and pharmacy benefit managers (PBMs) as the best way of lowering prices for patients.

The rise of vertical integration in the US payer landscape

But how can manufacturers respond to these new customers? PBM within a payer: Anthem. ... Third, IngenioRx’s goals may differ from those of typical carve-out PBMs.

Can new data aggregators shift the balance of power away from pharma?

In the latter case think biotechs and PBMs.) The industry’s strategic response has usually been jump-started by M&A, since organic growth driven by R&D-led changes were

Public affairs